Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Neil Barth, Gregory Bortz, Dov Perlysky

Premium

Agendia has hired Neil Barth to be its chief medical officer. Barth has 35 years of experience as a physician and in genomic biomarker development, and he led a staff of 1,400 physicians at Hoag Hospital in Newport Beach, Calif.


Enzo Biochem's shareholders have re-elected Gregory Bortz and Dov Perlysky to serve on the company's board of directors for three-year terms.

Bortz is founder and managing partner of Creo Capital Partners and he previously was senior VP of the Investment Banking Division of Lehman Brothers. Perlysky has been a managing member of the private investment firm Nesher and a director of the mutual fund Engex, and he has served on the board of directors at Pharma-Bio Serv and Highlands Bancorp.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.